Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4609 - Changes in CpG methylation of APC, CDH13, MLH1, MGMT, P16 and RASSF1A in gastric adenocarcinoma

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cancer Biology

Tumour Site

Gastric Cancer

Presenters

Natalia Timoshkina

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

N.N. Timoshkina1, O.I. Kit2, D.I. Vodolazhskiy1, N.V. Soldatkina2, Y.A. Gevorkyan2, N.S. Samoylenko2, D.A. Kharagezov2, M.N. Duritskiy3, A.V. Dashkov2, D.O. Kaymakchi2, D.S. Petrov2, S.A. Ilchenko2, V.A. Sustretov3, L.Y. Vladimirova4

Author affiliations

  • 1 Laboratory Of Molecular Oncology, Rostov Research Institute of Oncology, 344037 - Rostov-on-Don/RU
  • 2 Department Of Surgical oncology, Rostov Research Institute of Oncology, 344037 - Rostov-on-Don/RU
  • 3 Clinical Diagnostic Department, Rostov Research Institute of Oncology, 344037 - Rostov-on-Don/RU
  • 4 Medical Department, Rostov Research Institute of Oncology, 344037 - Rostov-on-Don/RU

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4609

Background

Stomach cancer (SC) is one of the most common cancers and the third leading cause of cancer-related deaths; however, it is often diagnosed at later stages. Literature data on epigenetic changes in stomach cancer and precancer, in particular on hypermethylation of tumor suppressor genes, indicate its important role in gastric tissue malignization.

Methods

Bisulfite pyrosequencing was used to study the CpG methylation in promoter sites of 6 tumor suppressor genes (APC, CDH13, MLH1, MGMT, P16 and RASSF1A). The study included paired bioptates of tumors and intact tissues obtained from 35 patients (25 men, 10 women, median age 67 years) with stomach cancer (G2-3 adenocarcinoma, T3-4N0-2M0).

Results

The rates of hypermethylation of the MGMT, P16 and RASSF1A genes amounted to 23%, 14% and 11% respectively. Increased methylation in the promoter site of the MLH1 gene was observed in one case only (11% vs 4%). Regulatory sites of CDH13 and APC genes in intact tissues were atypically hypermethylated in 80% of cases, which was obviously associated with functional characteristics of the gastric mucosa. However, the methylation of the promoter site of the CDH13 gene in non-tumor tissue was 2 times lower compared to the local tumor (p = 0.002) and 1.5 times lower compared to the tumor with lymph node metastases (p = 0.012). An association between the methylation of the P16 and RASSF1A genes and higher tumor grade G (p = 0.046) and increasing tumor sizes (T-classification, p = 0.028) was registered.

Conclusions

We observed hypermethylation of the promoter sites of the MGMT, P16 (CDKN2A) and RASSF1A genes in malignant stomach tissues compared to intact tissues which demonstrated the importance of disorders of repair processes (MGMT and RASSF1A) and mechanisms of regulation of the cell cycle (CDKN2A) in the malignization of stomach tissues. The methylation status of these genes can be a useful biomarker for early diagnosis of stomach cancer or possible therapeutic targets.

Clinical trial identification

Legal entity responsible for the study

Ministry of Health of the Russian Federation.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.